Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 03, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing share allocations for Non-Executive Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure regarding director share interests and does not contain financial performance data.
Material Changes
On July 1, 2007, Non-Executive Directors were provisionally allocated awards of Ordinary Shares and American Depository Shares (ADSs) for the service period of April 1, 2007, to June 30, 2007. The specific allocations were:
- Sir Christopher Gent: 2,197.45 ADSs
- Dr Stephanie Burns: 345.96 ADSs
- Mr Lawrence Culp: 691.93 ADSs
- Sir Crispin Davis: 1,528.66 ADSs
- Sir Deryck Maughan: 691.93 ADSs
- Dr Daniel Podolsky: 475.70 ADSs
- Sir Ian Prosser: 859.87 ADSs
- Dr Ronaldo Schmitz: 611.46 ADSs
- Mr Tom de Swaan: 525.48 ADSs
- Sir Robert Wilson: 477.71 ADSs
The Company and the Non-Executive Directors were informed of these allocations on July 2, 2007.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of director share transactions in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the final vesting status of the provisional share allocations listed for Non-Executive Directors.
- Confirm the total number of ADSs allocated to the board for the Q2 2007 service period.
- Review the company's broader 20-F annual report for comprehensive financial metrics absent in this 6-K filing.